Last checked at 23 Jun 2015 07:05
Proteome Sciences plc
Â
(the "Company")
Publication of Annual Report
Â
The Company announces that its Annual Report and Accounts for the year ended 31 December 2014, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at www.proteomics.com, and will be posted to shareholders imminently.
Â
ENDS
Â
Â
Media enquiries: Proteome Sciences plc | Â |
Christopher Pearce, Chief Executive Officer | Â |
Ian Pike, Chief Operating Officer | Tel : +44 (0)1932 865065 |
Geoff Ellis, Finance Director | Â |
 |  |
 |  |
Cenkos (Nominated Adviser) | Tel : +44 (0)20 7397 8900 |
Mark Connelly/Callum Davidson | Â |
 |  |
finnCap (Joint broker) | Â |
Geoff Nash | Tel : +44 (0)20 7220 0563 |
 |  |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
 | Mobile +44(0)7979 900733 |
 |  |
Â
Â
Â
Â
Â
Â
Â
Â
Notes for editors:
Â
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Servicesâ„¢ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.
Â
Â